Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies

v3.3.0.814
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies
3 Months Ended
Sep. 30, 2015
Notes to Financial Statements  
Business Description and Accounting Policies [Text Block]
Note 1. Basis of Presentation and Summary of Significant Accounting Policies:
 
The interim consolidated financial statements of Bio-Techne Corporation (formerly Techne Corporation) and subsidiaries, (the Company) presented here have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10-Q and Article 10 of Regulation S-X. They reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are of a normal recurring nature.
 
Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These interim unaudited condensed consolidated financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2015, included in the Company's Annual Report on Form 10-K for fiscal 2015. A summary of significant accounting policies followed by the Company is detailed in the Company's Annual Report on Form 10-K for fiscal 2015. The Company follows these policies in preparation of the interim unaudited condensed consolidated financial statements.
 
Available-For-Sale Investments:
 
The Company's available-for-sale securities are carried at fair value using Level 1 and Level 2 inputs. The fair value of the Company's available-for-sale investments at September 30, 2015 and June 30, 2015 were $38.4 million and $56.4 million, respectively. The decrease was caused by the maturity of $3.9 million of available for sale securities with the remainder due to the change in the fair value of the Company's investment in ChemoCentryx, Inc. (CCXI). The amortized cost basis of the Company's available-for-sale investments at September 30, 2015 and June 30, 2015 were $29.5 million and $33.6 million, respectively.
 
 
Inventories:
 
Inventories consist of (in thousands):
 
 
 
September 30,
 
 
June 30,
 
 
 
2015
 
 
2015
 
Raw materials
  $ 22,874     $ 15,892  
Finished goods
    36,093       33,685  
Inventories, net
  $ 58,967     $ 49,577  
 
At September 30, 2015, the Company had $59.0 million of inventory compared to $50.0 million as of June 30, 2015. The increase is primarily driven by the acquisition of Cliniqa Corporation in July 2015. At both September 30, 2015 and June 30, 2015, the Company had approximately $24 million of excess protein, antibody and chemically-based inventory on hand which was not valued.
 
 
4

 
 
 
Property and Equipment:
 
Property and equipment consist of (in thousands):
 
 
 
September 30,
 
 
June 30,
 
 
 
2015
 
 
2015
 
Land
  7,568     $ 7,370  
Buildings and improvements
    161,183       156,965  
Machinery and equipment
    76,281       74,385  
Property and equipment, cost
    245,032       238,720  
Accumulated depreciation and amortization
    (112,180     (108,971
)
Property and equipment, net
  $ 132,852     $ 129,749  
 
Intangible Assets:
 
Intangible assets consist of (in thousands):
 
 
 
September 30
 
 
June 30,
 
 
 
2015
 
 
2015
 
Developed technology
  $ 125,261     $ 108,887  
Trade names
    64,009       63,867  
Customer relationships
    190,340       167,494  
Non-compete agreements
    3,279       3,298  
Intangible assets
    382,890       343,546  
Accumulated amortization
    (57,494     (50,707
)
Intangible assets, net
  $ 325,396     $ 292,839  
 
Changes to the carrying amount of net intangible assets for the quarter ended September 30, 2015 consist of (in thousands):
 
Beginning balance
  $ 292,839  
Acquisitions
    46,100  
Amortization expense
    (7,411
)
Currency translation
    (6,132
)
Ending balance
  $ 325,396  
 
The estimated future amortization expense for intangible assets as of September 30, 2015 is as follows (in thousands):
 
 
 
 
 
 
2016
  $ 21,312  
2017
    27,532  
2018
    27,532  
2019
    26,721  
2020
    26,401  
2021
    26,401  
Thereaafter
    169,497  
    $ 325,396  
 
 
5

 
 
 
Goodwill:
 
Changes to the carrying amount of goodwill for the quarter ended September 30, 2015 consist of (in thousands):
 
Beginning balance
  $ 390,638  
Acquisitions
    43,000  
Currency translation
    (6,321
)
Ending balance
  $ 427,317